Saxenda denials in California external review
In the California DMHC record, independent physician reviewers decided 51 published external-review cases involving Saxendaand overturned the plan’s denial in 86.3%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
By condition
| Condition | Decisions | Overturned |
|---|---|---|
| Obesity | 48 | 87.5% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: The patient has been diagnosed with impaired fasting glucose, hypothyroidism, hyperlipidemia and obesity. The patient’s body mass index (BMI) was 36.48 kg/m². She has been treated with Saxenda in the past for weight loss. The patient was started on a low calorie, high protein diet to facilitate weight loss. The patient’s BMI was 35.48 kg/m². The patient was being treated with a trial of Saxenda and high protein diet with intermittent fasting, resulting in a six-pound weight loss. The patient has requested authorization and coverage for Saxenda 18 mg/3 mL. The Health Plan denied the request and reported the requested medication is not medically necessary for the treatment of this patient. At issue in this case is whether Saxenda 18 mg/3 mL is medically necessary for the treatment of the patient’s medical condition.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Saxenda. Findings: In this case, the records document that this patient has not responded well to treatment of obesity with phentermine, topiramate, and Wellbutrin. The provider noted that the patient was treated with phentermine with loss of 15 pounds but they regained the weight. The patient was subsequently treated with phentermine on two occasions with loss of 10 pounds followed by loss of three to four pounds. The patient has also been managed with a combination of Topamax and phentermine without significant weight loss. Treatment with Wellbutrin for depression resulted in weight gain.
Where the denial was upheld
Findings: The physician reviewer found that a patient with a history of cholecystectomy, laparoscopic adjustable gastric banding (LAP band) surgery, sleep apnea, hypothyroidism, and migraines. has requested authorization and coverage for Saxenda. Obesity is a disease associated with a significant increase in mortality and many health risks, including type 2 diabetes mellitus, hypertension, dyslipidemia, and coronary heart disease. Weight loss in people with overweight and obesity is associated with a reduction in mortality.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Saxenda pen-injection. Government regulators approved the use of Saxenda for chronic weight management in patients with a body mass index (BMI) of 30 kg/m2 or higher, or a BMI of 27 kg/m2 or higher and who have at least one weight-related condition. The regulators asserted that Saxenda is a therapy to be implemented in addition to a reduced-calorie diet and greater physical activity. One study concluded that Saxenda induces and sustains weight loss in patients with obesity. The authors noted that Saxenda’s efficacy is comparable to other available weight loss agents. In this case, the patient has a history of overweight and hypertension. The patient’s most recent weight was reportedly 184 pounds.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
Why plans deny Saxenda — and what reviewed cases show
Saxenda (liraglutide) is FDA-approved for: chronic weight management. An on-label indication can be important evidence when a denial frames the requested use as unproven or cosmetic.
Weight-loss benefit exclusions
As a dedicated anti-obesity medication, Saxenda gets swept up in category exclusions. The counter is the same as for the newer agents: obesity is a diagnosed chronic condition, and the denial letter must point to actual plan language.
“Use a newer agent” formulary steering
Some plans prefer newer weekly GLP-1s and deny daily liraglutide; others do the reverse and demand Saxenda before covering newer drugs. Either way, the prescriber's rationale for this agent — tolerability, history, dosing needs — is what the exception process weighs.
BMI and comorbidity thresholds
Coverage criteria track the label's BMI framework, and denials most often cite missing chart documentation of BMI or a weight-related comorbidity rather than any dispute about the medicine.
If the plan demands a different agent first, file a step-therapy exception with prescriber documentation of why liraglutide is the appropriate choice — prior outcomes, tolerability, or contraindications to alternatives.
Evidence cited in overturned Saxenda decisions
- Document BMI history and weight-related comorbidities directly in the appeal packet — don't assume the plan pulled the chart.
- Include prior weight-management attempts (programs, medications, outcomes) to satisfy or preempt step-therapy criteria.
- If steered toward a different agent, have the prescriber state the clinical reason Saxenda fits — the published record shows reviewers take that seriously.
The published California record contains 51 external-review decisions involving Saxenda; 86.3% were overturned. This historical rate does not predict another case. For the full class-wide picture — cross-indication strategy, exclusion language, and the record for every GLP-1 drug — see the GLP-1 denial appeal guide.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Saxenda, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY